Report Sections

See All Reports

  • HP:0001513: Obesity
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001513: Obesity

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (21)


    Name (Synonyms) Correlation
    drug1742 Higher-dose Wiki 0.30
    drug3351 Response and Attention Training Wiki 0.30
    drug1014 Computer Based Response Training Weight Loss Intervention Wiki 0.30
    Name (Synonyms) Correlation
    drug2884 Phentermine 37.5 Mg Wiki 0.30
    drug1636 Generic Response Training Control Intervention Wiki 0.30
    drug512 Bariatric procedures Wiki 0.30
    drug525 Basic Go NAPSACC Wiki 0.30
    drug3100 Project Health Wiki 0.30
    drug1390 Enhanced Go NAPSACC Wiki 0.30
    drug1483 FBT Wiki 0.30
    drug4557 low-dose Wiki 0.30
    drug1221 Dietary program Wiki 0.30
    drug3131 Psilocybin Wiki 0.30
    drug1484 FBT+Variety Wiki 0.30
    drug3931 Telemedicine to remote outpatient visit in bariatric patient Wiki 0.30
    drug2377 Middle-dose Wiki 0.30
    drug4631 online KKH Sports Singapore Program with Usual Care Wiki 0.30
    drug1462 Exposure to the Dutch measures due to the Covid-19 pandemic. Wiki 0.30
    drug1446 Exercise program Wiki 0.21
    drug4168 Usual Care Wiki 0.10
    drug2916 Placebo Wiki 0.01

    Correlated MeSH Terms (12)


    Name (Synonyms) Correlation
    D009765 Obesity NIH 1.00
    D063766 Pediatric Obesity NIH 0.37
    D050177 Overweight NIH 0.30
    Name (Synonyms) Correlation
    D009767 Obesity, Morbid NIH 0.21
    D006963 Hyperphagia NIH 0.21
    D001068 Feeding and Eating Disorders NIH 0.10
    D016638 Critical Illness NIH 0.04
    D011024 Pneumonia, Viral NIH 0.03
    D014777 Virus Diseases NIH 0.03
    D011014 Pneumonia NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (2)


    Name (Synonyms) Correlation
    HP:0002591 Polyphagia HPO 0.21
    HP:0002090 Pneumonia HPO 0.02

    Clinical Trials

    Navigate: Correlations   HPO

    There are 11 clinical trials


    1 Translational Neuroscience: Response Training for Obesity Treatment

    This project will test whether a food response training intervention produces lasting body fat loss, use objective brain imaging to examine the mechanism of effect of this treatment and investigate the generalizability of the training to non-training foods, and examine factors that should amplify intervention effects to provide a test of the intervention theory. This novel treatment represents a bottom-up implicit training intervention that does not rely on executive control, prolonged caloric deprivation, and expensive clinicians to deliver, like behavioral weight loss treatments that have not produced lasting weight loss. If this computer-based response training intervention produces sustained body fat loss in overweight individuals, it could be easily implemented very broadly at almost no expense, addressing a leading public health problem.

    NCT03375853
    Conditions
    1. Obesity
    2. Hyperphagia
    3. Feeding and Eating Disorders
    Interventions
    1. Behavioral: Computer Based Response Training Weight Loss Intervention
    2. Behavioral: Generic Response Training Control Intervention
    MeSH:Obesity Hyperphagia Feeding and Eating Disorders
    HPO:Obesity Polyphagia

    Primary Outcomes

    Description: Change in participant's body fat percentage

    Measure: Body Fat Change

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Secondary Outcomes

    Description: Eating disorder symptoms as measured with the Eating Disorder Diagnostic Interview

    Measure: Change in Eating Disorder Symptoms

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Dietary Restraint, Emotional Eating, and External Eating (aggregate score) as measured by the Dutch Eating Behavior Questionnaire

    Measure: Dietary Restraint, Emotional Eating, and External Eating

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Chang in Disinhibited Eating as measured by the Three Factor Eating Questionnaire

    Measure: Change in Disinhibited Eating Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Eating When Not Hungry as measured by the Eating in the Absence of Hunger Questionnaire

    Measure: Change in Eating in the Absence of Hunger Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Problematic eating patterns associated with symptoms of addictive behaviors as measured by the Yale Food Addiction Scale

    Measure: Change in Food Addiction Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Physical Activity as measured by the Paffenberger Questionnaire

    Measure: Change in Physical Activity

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Substance use frequency (i.e., number of times per day) for alcohol of participants as measured by the Daily Drinking Questionnaire

    Measure: Change in Alcohol Use Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Substance use frequency (i.e., number of times per day) for common recreational drugs of participants as measured by the Daily Drug Taking Questionnaire

    Measure: Change in Substance Use Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Participant behavioral response to food pictures, and subjective palatability rating

    Measure: Change in Participant Ratings of Unhealthy Food Palatability

    Time: Baseline, 1 month

    Description: Change in Participant behavioral response to food pictures, and willingness to pay given dollar amounts (aggregate score) for the pictured food

    Measure: Change in Participant Ratings of Food Monetary Value

    Time: Baseline, 1 month

    Description: Change Participant food craving behaviors as measured by the Food Craving and Liking Scale

    Measure: Change in Food Craving and Liking Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Participant BMI using standard methods of calculation

    Measure: Change in Body Mass Index

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in mean R-Peak Amplitude measured using three-lead ECG using PowerLab 8 Diagnostic Suite

    Measure: Change in mean R-Peak Amplitude

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Heart Rate Variability measured using three-lead ECG using PowerLab 8 Diagnostic Suite

    Measure: Change in Heart Rate Variability

    Time: Baseline, 1 month, 3 months, 6 months, 12 months
    2 Enhancing Effectiveness of a Dissonance-Based Obesity Prevention Program

    This project seeks to improve the effectiveness of a novel dissonance-based obesity prevention program that has reduced future BMI gain and overweight/obesity onset by (a) experimentally testing whether implementing it in single- versus mixed-sex groups, which should increase dissonance-induction that contributes to weight gain prevention effects, and (b) experimentally testing whether adding food response and attention training, which theoretically reduces valuation of and attention for high-calorie foods, increases weight gain prevention effects. This randomized trial would be the first to experimentally manipulate these two factors in an effort to produce superior weight gain prevention effects. A brief effective obesity prevention program that can be easily, inexpensively, and broadly implemented to late adolescents at risk for excess weight gain, as has been the case with another dissonance-based prevention program, could markedly reduce the prevalence of obesity and associated morbidity and mortality.

    NCT03710746
    Conditions
    1. Overweight and Obesity
    Interventions
    1. Behavioral: Project Health
    2. Behavioral: Response and Attention Training
    MeSH:Obesity Overweight
    HPO:Obesity

    Primary Outcomes

    Description: Change in percentage of body fat (Not collected during COVID-19 shelter-at-home order)

    Measure: Body Fat

    Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 months

    Description: Change in BMI (Not collected during COVID-19 shelter-at-home order)

    Measure: Body Mass Index (BMI)

    Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 months

    Secondary Outcomes

    Description: Change in weight concerns. Scale scores range from 0 to 42 with higher scores being indicative of higher weight concerns.

    Measure: Weight Concerns Scale from the Eating Disorder Examination Questionnaire (EDE-Q)

    Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 months

    Description: Change in depressive symptoms

    Measure: Beck Depression Index (BDI)

    Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 months

    Description: Change in eating disorder symptoms

    Measure: Eating Disorder Interview (EDDI)

    Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 months
    3 A Hybrid Effectiveness-implementation Trial of Go NAPSACC: A Childcare-based Obesity Prevention Program

    This study will compare the effectiveness and cost of Basic and Enhanced delivery models for Go NAPSACC on child care centers' use of evidence-based nutrition and physical activity practices. Technical assistance (TA) coaches from Child Care Aware of Kentucky will lead delivery. Half of the TA coaches will deliver Go NAPSACC using the Basic model and the other half will deliver the program using the Enhanced model. It is hypothesized that the Enhanced model will result in greater use of evidence-based nutrition and physical activity practices and will also be more cost effective.

    NCT03938103
    Conditions
    1. Obesity
    Interventions
    1. Behavioral: Enhanced Go NAPSACC
    2. Behavioral: Basic Go NAPSACC
    MeSH:Obesity
    HPO:Obesity

    Primary Outcomes

    Description: Each center's nutrition and physical activity environment will be assessed using the Environment and Policy Assessment and Observation- Self Report (EPAO-SR), a self-report measure filled out through online surveys by child care center directors and preschool classroom lead teachers. When directors upload a month of menus and policy handbooks, a trained staff member will fill out relevant items. If not, the directors will fill out those items. An overall nutrition and physical activity environment score will be derived with scores ranging from 0-57, where higher scores indicate better (more supportive) nutrition and physical activity environments.

    Measure: Change in nutrition and physical activity environment score from baseline to 12 months

    Time: Measures collected 3-12 weeks prior to start of intervention and 1-8 weeks post-12-month intervention

    Secondary Outcomes

    Description: The number of participating centers will be captured by the Go NAPSACC website and extracted using the Go NAPSACC Registration Report. This Registration Report documents all child care centers that have completed registration and created a Go NAPSACC account. Creation of an account will be used to define participation/adoption.

    Measure: Number of participating centers

    Time: Measures collected 3-12 weeks prior to start of intervention

    Description: Percent of Go NAPSACC core program components completed will be captured by the Go NAPSACC website and extracted using the Detailed Activity Report. These data will serve as indicators of fidelity. The Detailed Activity report captures centers' completion of key steps in the improvement process (completion of a self-assessment, selection of goals, creation of action plans, etc.). For this study, centers will be expected to complete 2 cycles of the improvement process, including all key steps. These data will be used to calculate the percentage of steps completed.

    Measure: Percent of Go NAPSACC core program components completed by centers

    Time: Measures collected during the 1 year intervention period.

    Description: Percent of Go NAPSACC core program components completed will be captured by the Go NAPSACC website and extracted using the TA Activity Report. These data will serve as indicators of fidelity. The TA Activity Report all coaches to document their implementation activities. Based on their prescribed implementation model (basic or enhanced), these data will be used to calculate the percentage of prescribed implementation activities completed.

    Measure: Percent of Go NAPSACC core program components completed by TAs

    Time: Measures collected during the 1 year intervention period.

    Description: Child nutrition self-assessment scores are captured on the Go NAPSACC website each time child care centers complete a self-assessment for that module. Each self-assessment item is scored 1-4 points, where higher points indicate closer compliance with best practices. Responses are then used to calculate a total score (total points/total possible points x 100). As an indicator of maintenance, self-assessment data will be extracted using the Go NAPSACC Child Nutrition Self-Assessment Report pulled immediately post-intervention, as well as 6, 12, and 18 months post to calculate changes in scores over time. No change and/or positive change would indicate that the intervention effect was maintained.

    Measure: Changes in child nutrition self-assessment scores at 6 and 12, and 18 months post-intervention

    Time: Measures will be collected at 6, 12, and 18 months post-intervention

    Description: Physical activity self-assessment scores are captured on the Go NAPSACC website each time child care centers complete a self-assessment for that module. Each self-assessment items is scored 1-4 points, where higher points indicate closer compliance with best practices. Responses are then used to calculate a total score (total points/total possible points x 100). As an indicator of maintenance, self-assessment data will be extracted using the Go NAPSACC Physical Activity Self-Assessment Report pulled immediately post-intervention, as well as 6, 12, and 18 months post to calculate changes in scores over time. No change and/or positive change would indicate that the intervention effect was maintained.

    Measure: Changes in physical activity self-assessment scores at 6, 12, and 18 months post-intervention

    Time: Measures will be collected at 6, 12, and 18 months post-intervention

    Description: Contextual factors will be assessed using surveys completed by directors, teachers, and TA coaches. Specifically, Fernandez's CFIR Inner Setting measure will be used to assess Culture, Culture Stress, Culture Effort, Implementation Climate, Leadership Engagement, and Available Resources. Items are scored 1-5. Items within subscales will be averaged to determine the scale score. Higher scores indicate better contextual factors. These scores will be used to examine how context predicts changes in nutrition and physical activity environment scores.

    Measure: Contextual factors scores- Culture, implementation climate, leadership engagement, and available resources

    Time: Measures collected 3-12 weeks prior to the start of intervention

    Description: Contextual factors will be assessed using surveys completed by directors, teachers, and TA coaches. TCU's Organizational Readiness for Change Survey will be used to assess Networks and Communications and Access to Knowledge and Information. Items are scored 1-5 and items within subscales will be averaged to determine the scale score. Higher scores indicate better contextual scores. These scores will be used to examine how context predicts changes in nutrition and physical activity environment scores.

    Measure: Contextual factors scores- Networks and communications and access to knowledge and information

    Time: Measures collected 3-12 weeks prior to the start of intervention

    Description: Contextual factors will be assessed using surveys completed by directors, teachers, and TA coaches. Seward's Theoretical Domains Framework Questionnaire will be used to assess Knowledge, Beliefs and Consequences, and Self-Efficacy. Items are scored 1-7. Items within subscales will be averaged to determine the scale score. Higher scores indicate better contextual scores. These scores will be used to examine how context predicts changes in nutrition and physical activity environment scores.

    Measure: Contextual factors scores- Knowledge, beliefs, and consequences and self-efficacy

    Time: Measures collected 3-12 weeks prior to the start of intervention

    Description: Costs of implementation include TA coaches time and any resources required to train and support centers for 12 months. Cost tracking will use the TA Activity Log to capture TA coaches' time and TA coaches will be asked to fill out a supplemental log of additional costs (e.g., mileage, printing). These data will be combined to calculate the total cost per center for implementing Go NAPSACC. Average cost per center for basic and enhanced implementation models will also be calculated. To explore the cost-effectiveness of basic and enhanced implementation models, these data will be combined with data on the change in nutrition and physical activity environment scores to calculate the incremental cost-effectiveness ratio (average incremental cost of delivering Enhanced Go NAPSACC relative to Basic Go NAPSACC divided by the average incremental change in effectiveness from delivering Enhanced Go NAPSACC relative to Basic Go NAPSACC).

    Measure: Cost of basic and enhanced implementation models

    Time: Measures collected throughout the 1 year intervention period

    Description: Center-level dietary intake of food served to preschool children will be assessed via the foods and beverages provided section of the EPAO-SR as filled out online by the director on 2 different days of the week. Center-level served dietary intake data will be used to calculate Healthy Eating Index 2015 (HEI2015) scores to produce a center-level estimate of children's diet quality. Scores will range from 0-100, where scores closer to 100 will indicate higher diet quality.

    Measure: Change in children's diet quality served at child care from baseline to 12 months (exploratory)

    Time: Measures collected 3-12 weeks prior to start of intervention and 1-8 weeks post-12-month intervention

    Description: A center-level score for time provided for active play for preschool children will be assessed via the daily activities section of the of the EPAO-SR as filled out online by 2 classroom teachers on 2 different days of the week. Active play time blocks will be summed each day and then averaged across the 2 days to calculate a center-level estimate, where higher scores indicate more active play time provided.

    Measure: Change in time provided for physical activity for preschool children at child care from baseline to 12 months (exploratory)

    Time: Measures collected 3-12 weeks prior to start of intervention and 1-8 weeks post-12-month intervention
    4 Families Becoming Healthy Together

    The investigators plan to implement a novel limited RED (high-energy-dense) food variety prescription within a 18-month FBT to examine its effect on 18-month body mass index (BMI). This will be the first randomized control trial to examine how habituation rate, assessed via salivary habituation, mediates reduction in RED food intake, overall energy intake, and reductions in BMI over time, as well as if baseline habituation rate is a behavioral phenotype that moderates BMI outcomes. One hundred fifty-six children aged 8 to 12 years at > 85th percentile BMI will be randomized to one of two, 18-month interventions compared in our 6-month pilot study: FBT (family-based behavioral obesity treatment) or FBT+Variety. Child and adult caregiver assessments will occur at 0, 6, 12, and 18 months on anthropometrics, dietary intake (RED food variety, energy, and diet quality), habituation, and physical activity.

    NCT04027426
    Conditions
    1. Obesity
    2. Childhood Obesity
    Interventions
    1. Behavioral: FBT
    2. Behavioral: FBT+Variety
    MeSH:Obesity Pediatric Obesity
    HPO:Obesity

    Primary Outcomes

    Description: Child's and adult caregiver's weight will be assessed by an electronic scale and height will be measured by a stadiometer.

    Measure: Child and adult body mass index

    Time: Change from 0 to 6, and 6 to 18 months

    Description: To assess habituation of salivary responses to food cues, whole mouth parotid salivary flow will be measured using the Strongin-Hinsie Peck method. Two measures will be taken, one with juice and one with food.

    Measure: Child and adult salivary habituation

    Time: Change from 0 to 6, and 6 to 18 months

    Secondary Outcomes

    Description: Dietary intake for both the child and adult caregiver will be assessed by 3 (2 weekdays and 1 weekend day) 24-hour dietary phone recalls, using the five-step, multiple-pass method. Variables of interest will be the variety of RED foods consumed over the three days; and the mean over the three days of daily servings and kcal from RED foods, kcal, energy density (kcal/g), and Healthy Eating Index (HEI)-2015. Adherence to the prescriptions in the two conditions will be examined. At 6, 12, and 18 months, the percentage of goals met each day will be calculated, with a mean percentage calculated. We will also provide a detailed list of snack foods to participants, and they will be asked to indicate which of the foods on the list were eaten during the previous month, regardless of quantity consumed.

    Measure: Child and adult dietary Intake

    Time: Change from 0 to 6, and 6 to 18 months

    Description: The wGT9x (ActiGraph, LLC, Pensacola, FL) will objectively measure time spent in MVPA (physical activity at > 3.0 metabolic equivalents units).

    Measure: Child and adult physical activity via wGT3X-BT

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Percent overweight (%OW) will also be calculated (100*[BMI/50th percentile BMI for child age and sex]).

    Measure: Child percent overweight

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Waist circumference (WC) will be measured using standard procedures.

    Measure: Child and adult waist circumference

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Parent time scarcity and fatigue as barriers to planning and preparing meals will measure frequency of occurrence of these barriers.

    Measure: Meal planning, preparation, and grocery shopping

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Child eating pathology will be assessed using the Kid's Eating Disorder Survey

    Measure: Child eating pathology

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Self-reported inventory of foods available in the household will be assessed

    Measure: Home Food Inventory

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Usual sleeping and waking time will be collected

    Measure: Child and Adult Sleep Habits

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Parent-report measure of commonly occurring routines in school-aged children will measure the frequency of occurrence of routines in children.

    Measure: Child Routines

    Time: Change from 0 to 6, and 6 to 18 months

    Description: Total number of weekly, and type, of self-monitoring records (hard copy or electronic) completed will be assessed. Number of treatment sessions attended will be recorded.

    Measure: Compliance and process data

    Time: 6, 12, and 18 months
    5 Adapting the US-based Clinic-community Model of Child Obesity Treatment Into an Online Intervention Model in Singapore During COVID-19

    Background: The Coronavirus 2019 (COVID-19) is an infectious disease, which was first identified in December 2019 and has then spread rapidly around the world. COVID-19 spreads mainly through respiratory droplets and causes people to experience mild to moderate respiratory illness. On 11 March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. With the surge in cases and to contain the spread of this disease, Singapore implemented a circuit breaker to reduce movements and interactions in public and private places. People are advised to stay at home and practise social distancing. With restrictions in movements, parents and children are likely to be more sedentary in this pandemic. There is an urgent need to move face-to-face interventions to online interventions as it is important to be active in this period. Childhood obesity threatens the health of US and Singapore populations. In the US, 30% of children are overweight, 17% have obesity, and 8% have severe obesity. In Singapore, 13% of children have obesity, and approximately half of all overweight children live in Asia. In both countries the prevalence is increasing, especially amongst the lower income populations, and is associated with future cardiovascular and metabolic disease. In US, obesity is most prevalent in Black and Hispanic populations and in Singapore, obesity affects Malays and Indians disproportionately. The underlying drivers and potential solutions thus share many common factors. The current evidence shows a clear dose-response effect with increasing number of hours of treatment, with a threshold for effectiveness at > 25 hours over a 6-month period. A key gap in delivering this recommendation is meeting the intensity, and delivering comprehensive treatment that is culturally relevant, engaging to families, and integrated within the community context. The study is an online pilot randomised controlled trial among children aged 4-6 with obesity, in Singapore, to test a novel school-clinic-community online intervention, the KK Hospital (KKH) Sports Singapore program, for child obesity treatment with usual care. The primary outcome is intensity of treatment as measured by hours of exposure to intervention. The online KKH Sports Singapore program involves 3-4 weekly online sessions of physical activity and nutrition lessons for children and parents.

    NCT04395430
    Conditions
    1. Pediatric Obesity
    2. Clinical Trial
    Interventions
    1. Behavioral: Usual Care
    2. Behavioral: online KKH Sports Singapore Program with Usual Care
    MeSH:Obesity Pediatric Obesity
    HPO:Obesity

    Primary Outcomes

    Description: Measure intensity of intervention from baseline to 6 months. Intensity is measured using the number of hours of exposure to intervention.

    Measure: Intensity of intervention

    Time: 6 months

    Secondary Outcomes

    Description: Measure change in cardiorespiratory fitness at baseline, 3 months and 6 months using the 3 minute step test.

    Measure: Change in cardiorespiratory fitness

    Time: Baseline, 3 months and 6 months

    Description: Measure change in quality of life at baseline, 3 months and 6 months using the Paediatric Quality of Life Inventory (PedsQL; US version 4). PedsQL is a comprehensive and multi-dimensional construct that includes physical, emotional, and social functioning to assess quality of life in the children. It uses a 5-point Likert scale where 0= never, 1 = almost never, 2 = sometimes, 3 = often, 4 = almost always. Items will be reverse scored and linearly transformed to a 0-100 scale so that higher scores indicate better quality of life.

    Measure: Change in quality of life

    Time: Baseline, 3 months and 6 months

    Description: Measure the stabilisation or change in BMI at baseline, 3 months and 6 months. Body mass index (BMI) will be calculated as kg/m2.

    Measure: Change in BMI

    Time: Baseline, 3 months and 6 months

    Description: Measure change in self-esteem at baseline, 3 months and 6 months. Self-esteem is measured using the Behavioural Rating Scale of Presented Self-Esteem questionnaire. The first category of items consists of active displays of confidence, curiosity, initiative, exploration and independence while the second category consists of adaptive reactions to change or stress. It uses a four-point scale from 1-4 where higher scores indicate higher self-esteem.

    Measure: Change in self-esteem

    Time: Baseline, 3 months and 6 months

    Description: Measure change in eating behaviour at baseline, 3 months and 6 months. Eating behaviour is measured using the Child Eating Behaviour Questionnaire (CEBQ). The questionnaire consists of 35 items and measures food responsiveness, emotional over-eating, enjoyment of food, desire to drink, satiety responsiveness, slowness in eating, emotional under-eating and food fussiness using a 5-point Likert scale (1= never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always). Higher scores indicate higher level of behaviour in the respective dimensions.

    Measure: Change in eating behaviour

    Time: Baseline, 3 months and 6 months

    Description: Measure change in gross motor skills at baseline, 3 months and 6 months. Gross motor skills is measured using the Test of Gross Motor Development (Ver. 3.0). The first subtest, Locomotor, measures the gross motor skills that require fluid coordinated movements of the body as the child moves in one direction or another. The second subtest, Ball Skills, measure the gross motor skills that demonstrate efficient throwing, striking, and catching movements.

    Measure: Change in gross motor skills

    Time: Baseline, 3 months and 6 months

    Description: Measure change in caloric intake using a three day food diary at baseline, 3 months and 6 months.

    Measure: Change in caloric intake

    Time: Baseline, 3 months and 6 months

    Description: Measure change in physical activity using results from accelerometer to assess time spent on sedentary and moderate to vigorous physical activity at baseline, 3 months and 6 months.

    Measure: Change in physical activity

    Time: Baseline, 3 months and 6 months

    Description: Measure change in blood pressure at baseline, 3 months and 6 months. Blood pressure will be measured in mmHg via an electronic sphygmomanometer. Both systolic and diastolic blood pressure will be measured.

    Measure: Change in blood pressure

    Time: Baseline, 3 months and 6 months

    Description: Measure change in waist circumference at baseline, 3 months and 6 months. Waist circumference is measured at the narrowest point between the lower costal (rib) border and the iliac crest using a non-extensible steel tape.

    Measure: Change in waist circumference

    Time: Baseline, 3 months and 6 months

    Description: Measure change in number of servings of fruits and vegetables using a three day food diary at baseline, 3 months and 6 months .

    Measure: Change in servings of fruits and vegetables

    Time: Baseline, 3 months and 6 months
    6 Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near. Brief Correspondence on a Single Center Experience. Cohort Study

    Bariatric patients represent a peculiar and frail subset of subjects, constantly increasing. During the novel coronavirus disease outbreak, for the lockdown of any non-urgent and non-oncological activity, the access to healthcare services was severely limited, according to the International Federation for the Surgery of Obesity and Metabolic Disorders.

    NCT04407663
    Conditions
    1. Bariatric Surgery Candidate
    2. Patient Underwent Bariatric Surgery
    Interventions
    1. Other: Telemedicine to remote outpatient visit in bariatric patient
    MeSH:Obesity
    HPO:Obesity

    Primary Outcomes

    Description: Telemedicine to follow-up and identify sing or symptom of alarm in patient undergoing bariatric surgery or in established bariatric patients during COVID-19 outbreak

    Measure: Evaluation of feasibility of telemedicine in outpatient visit in bariatric patients

    Time: 2 months
    7 The Influence of the Covid-19 Pandemia on the Health Behaviour of Primary School Children (and Their Parents) - COVID-19, Obesity and Lifestyle in Children

    This study aims to evaluate the impact of the COVID-19 pandemic and its measures on lifestyle in Dutch children between 4 - 18 years.

    NCT04411511
    Conditions
    1. Covid-19
    2. Obesity, Childhood
    3. Lifestyle
    4. Lifestyle, Healthy
    5. Overweight, Childhood
    6. Children, Only
    7. Family
    Interventions
    1. Other: Exposure to the Dutch measures due to the Covid-19 pandemic.
    MeSH:Obesity Pediatric Obesity Overweight
    HPO:Obesity

    Primary Outcomes

    Description: Weight development of the child. Weight (in kg) will be measured using scales at home, with clear instructions.

    Measure: Change in weight child

    Time: Every 2 weeks until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs). Three months after the "measures"-period, 1 follow-up moment.

    Description: Weight development of the parents. Weight (in kg) will be measured using scales at home, with clear instructions.

    Measure: Change in weight parents

    Time: Every 2 weeks until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs, hereafter: "coronacrisis-period"). Three months after the "measures"-period, 1 follow-up moment.

    Secondary Outcomes

    Description: eating behaviour during measures due to the coronacrisis, measured with an online questionnaire.

    Measure: Eating behaviour

    Time: Every month until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs). Three months after the "measures"-period, 1 follow-up moment.

    Description: COVID-19 related symptoms and adherence to governmental measures, measured with an online questionnaire.

    Measure: Symptoms

    Time: Every 2 weeks until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs). Three months after the "measures"-period, 1 follow-up moment.

    Description: Daystructure of children during the coronacrisis, measured with an online questionnaire.

    Measure: Day structure

    Time: Every month until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs). Three months after the "measures"-period, 1 follow-up moment.

    Description: Physical activity behaviour children during the coronacrisis, measured with the Baecke questionnaire.

    Measure: Physical activity

    Time: Every month until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs). Three months after the "measures"-period, 1 follow-up moment.

    Description: Screentime during the the coronacrisis, measured with an online questionnaire.

    Measure: Screentime

    Time: Every month until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs). Three months after the "measures"-period, 1 follow-up moment.

    Description: Online possibilities for working on a healthy lifestyle, such as challenges regarding nutrition and physical activity, measured with an online questionnaire.

    Measure: Online possibilities

    Time: Every month until end of the Dutch governement measures affecting children (e.g. fully opening of the schools and sportclubs). Three months after the "measures"-period, 1 follow-up moment.

    Description: Quality of life during the coronacrisis, measured with the Kidscreen-27.

    Measure: Quality of life in children

    Time: Once in first month of the study and once within three months after COVID-19 measures are scaled down.

    Description: Parenting practices regarding eating behaviour and physical activity, measured with a questionnaire.

    Measure: Parenting practices

    Time: Once in first month of the study and once within three months after COVID-19 measures are scaled down.

    Other Outcomes

    Description: Qualitative data on lifestyle in children during the coronacrisis, by semi-structured interviews.

    Measure: Qualitative data on lifestyle in children

    Time: Up to approximately 1 year
    8 Obesity as a Risk Factor for Mortality of Critically Ill Patients With Coronavirus Disease 2019 (COVID-19): a Cohort Study of the First Wave in Nancy, France

    Disproportionate impact of COVID-19 in patients with obesity is now well established. Obesity is associated with severe forms of COVID-19 and may be a risk factor of intensive care unit (ICU) admission. Obesity is associated with COVID-19 related hospital death in a large United Kingdom cohort study. However, there is a gap of knowledge on assessment of outcomes such as severity of Acute Respiratory Distress syndrome (ARDS), duration of hospitalisation and mortality in ICU. Moreover, an obesity survival paradox has been observed in patients with ARDS. This raises the question whether the obesity paradox has been broken by COVID-19. The investigators aim to explore risk factors of in-ICU death for patient with COVID-19, including obesity and other chronic diseases and to describe the clinical course and outcomes, including the management of acute respiratory failure and other intensive care management.

    NCT04425213
    Conditions
    1. COVID
    2. Severe Acute Respiratory Syndrome
    3. Obesity
    4. Comorbidities and Coexisting Conditions
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Obesity Critical Illness
    HPO:Obesity

    Primary Outcomes

    Description: number of fatal cases

    Measure: ICU mortality

    Time: through study completion, an average of 14 days

    Secondary Outcomes

    Description: number of patients with invasive mechanical ventilation

    Measure: Invasive mechanical ventilation

    Time: through study completion, an average of 14 days

    Description: number of fatal cases

    Measure: In-hospital mortality

    Time: through study completion, an average of 21 days
    9 Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.

    The first person-to-person Coronavirus disease (COVID-19) transmission in Italy was reported on Feb 21st, 2020, causing one of the most massive outbreak in Europe so far that stopped immediately all elective surgical procedures. Bariatric surgery represents the most effective treatment to obtain an important, long-term weight loss and comorbidities' resolution, including respiratory disorders. A sensitive decrease of epidemic has been observed lately and a gradual and progressive stop of the lockdown (phase 2-3) was planned, when the virus is supposed to be under control and protocols are guiding the restart of the elective bariatric surgery. Several questions are currently open: Laparoscopic bariatric surgery is safe in the phase 2-3? What's the expected complications rate? The actual hospital protocols are effective to minimize the risk of postoperative COVID-19 infection? Aim: to analyse results of bariatric surgery during phase 2-3 COVID-19 pandemic in Italy. Primary end point: 30 days COVID-19 infection, mortality and complications. Secondary end points: readmission rate 30 days, reoperations for any reason related to surgery. Study design: prospective multicenter observational. Setting: Italian National Health Service 8 high-volume bariatric centres. Enrollment criteria: No previous Covid-19 infection; Primary, standard IFSO approved bariatric procedures; No concomitant procedure; No previous major abdominal surgery; >18<60 years old; Compensated comorbidities; Official SICOB's surgical informed consent given, including COVID-19 addendum; Adherence to very restrictive protocols regarding: hospital admission, management of in-hospital patients and after discharge. Follow-up: scheduled outpatient visit 30th postoperative day. Data evaluation: all the cases performed during July/December 2020 will be collected in a prospective database. Patients operated during the period July/December 2019 in the same centers will be considered comparative group (control). Expected results: Transparent information to the patients, and the introduction of the COVID-19 protocol concerning patients and health-professionals protection, should guarantee a safe restart of bariatric surgery in Italy. The network of 8 high-volume centers sharing information and protocols in this "unexplored" period will be a guarantee for patients' safety. Bariatric surgery should induce a postoperative amelioration of the comorbidities reducing the risks in case of a second outbreak.

    NCT04480034
    Conditions
    1. Bariatric Surgery Candidate
    2. Covid19
    3. Complication of Surgical Procedure
    4. Pneumonia, Viral
    5. Viral Infection
    6. Obesity, Morbid
    7. Safety Issues
    8. Readmission
    Interventions
    1. Procedure: Bariatric procedures
    MeSH:Virus Diseases Pneumonia, Viral Pneumonia Obesity Obesity, Morbid
    HPO:Obesity Pneumonia

    Primary Outcomes

    Description: Postbariatric surgery COVID-19 infection, mortality and complications

    Measure: Postoperative COVID-19 infection

    Time: 30 postoperative days

    Secondary Outcomes

    Description: Complications, reoperations for any reason related to bariatric surgery.

    Measure: Complications related to bariatric surgery

    Time: 30 postoperative days
    10 Dose-ranging Study of Labisia Pumila Aqueous Ethanolic Standardized Extract (SKF7™) for Obesity: a Randomized, Double-blind, Placebo-controlled, Phase-2 Study

    This study has been designed as a randomized, double blinded, multi-centric, placebo controlled, and phase II dose-ranging study. The herbal drug contains bioactive ingredients from Labisia pumila plant and it is an aqueous ethanolic standardized extract (SKF7™).

    NCT04557267
    Conditions
    1. Obesity
    Interventions
    1. Drug: low-dose
    2. Drug: Middle-dose
    3. Drug: Higher-dose
    4. Drug: Placebo
    MeSH:Obesity
    HPO:Obesity

    Primary Outcomes

    Description: Percentage of subjects whose Body Weight is lowered

    Measure: Change in body weight

    Time: 12 weeks

    Description: Change in waist and hip circumference

    Measure: Change in waist and hip circumferences

    Time: 12 weeks

    Description: Change in waist-hip ratio and waist-height ratio

    Measure: Change in the waist-hip and waist-height ratios

    Time: 12 weeks

    Description: Change in BMI in kg/m^2

    Measure: Change in Body Mass Index (BMI)

    Time: 12 weeks

    Secondary Outcomes

    Description: The change of body fat percentage

    Measure: Body fat percentage

    Time: 12 weeks

    Description: The amount of lean body mass will be calculated from body fat percentage

    Measure: Lean Body Mass

    Time: 12 weeks

    Other Outcomes

    Description: Abnormality of vital signs and laboratory test results

    Measure: Incidence of abnormal vital signs and of abnormal laboratory test results

    Time: 12 weeks

    Description: The incidence and percentage of Adverse events and serious adverse events

    Measure: Incidence of Adverse Events

    Time: 12 weeks
    11 The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits

    This study will study the effects associated with the prescription of phentermine in a virtual setting, comparing with prescription of phentermine via a standard face-to-face visit for patients with obesity or overweight.

    NCT04614545
    Conditions
    1. Obesity
    Interventions
    1. Drug: Phentermine 37.5 Mg
    2. Behavioral: Dietary program
    3. Behavioral: Exercise program
    MeSH:Obesity Overweight
    HPO:Obesity

    Primary Outcomes

    Description: The primary endpoint is mean change in body weight (%) from baseline (visit 1) to 12 weeks (visit 4) in body weight.

    Measure: Change in body weight (percentage)

    Time: 12 weeks

    Secondary Outcomes

    Description: Assessed as number of missed visits

    Measure: Adherence to weight management program

    Time: 12 weeks

    Description: Assessment of medication compliance

    Measure: Adherence to medication use

    Time: 12 weeks

    Description: Mean change in BMI from baseline to week 12

    Measure: Change in BMI

    Time: 12 weeks

    HPO Nodes


    HP:0001513: Obesity
    Genes 490
    NR2E3 WT1 LMNA TBX3 POGZ PROK2 DCC MID2 SDCCAG8 ZNF41 RAB39B LIMK1 CNKSR2 PRPF4 PDE11A RP2 USP27X BBS10 CTNNB1 KIDINS220 FGFR3 XYLT1 PDE6B TOPORS GP1BB BBS7 GATA4 ARL2BP KCNJ11 MLXIPL HS6ST1 CEP290 GHRL EGF TAF1 PRKAR1A SEC24C PROM1 BBS12 POMC NPHP1 CARTPT C8ORF37 APOE DMD ZBTB20 BBS2 SYNE2 BLK UBE3A CCDC141 TMEM43 FTSJ1 HCFC1 FEZF1 SOX2 CACNA1S CDH23 BBS7 EMD ELN IFT172 CEL MAGEL2 TMEM67 JMJD1C UFD1 NIN ARMC5 CREBBP MKKS PDE6A BAP1 FHL1 GTF2I NEUROD1 USH2A SIN3A KIF7 RBMX PCARE CXORF56 EXOC6B MCM3AP LEP TBX1 HERC2 MED12 PDX1 OTX2 USP9X ARL6 LZTFL1 PWAR1 ADRB3 BBS9 RPE65 REEP6 RLBP1 HNF1A ERMARD TTC8 POMGNT1 INPP5E WDPCP CUL4B SAG SDCCAG8 SDC3 HESX1 KMT2A BLK RAD21 SEMA4A MOG ATP6AP2 CEP164 ARL6 BBS12 POMC MAN1B1 CTSH ALMS1 HSD11B1 NPAP1 CDHR1 RERE BLM HCRT ARNT2 FLRT3 BBS4 ROM1 SNORD116-1 ARHGEF6 ZNF711 ZNF513 GDI1 GNAS VPS13B RP1 FTO DDX6 PCNT POU3F4 TULP1 DUSP6 MC4R PNPLA6 SYP CREBBP SPATA7 LMNA GABRA3 H6PD CA4 NIPBL GNAS MKRN3 FMR1 SNORD115-1 RP9 MC3R MKS1 BBS2 PHF6 SUFU GNAS-AS1 WDR11 TSPAN7 MERTK GNAS MTTP PRPF6 NR0B2 GNAS BAP1 PRKAR1A MYT1L HNF4A RAI1 DYNC2I2 RPGR BBS9 SMARCB1 NKAP RAB23 GUCA1B LAS1L ZNF365 ALMS1 PAX6 HDAC8 ATRX TRAF3IP1 HDAC8 KIAA1549 CNNM2 PROKR2 MOG SEMA3A BBS5 PAX6 LEPR LZTFL1 SYNE1 SNRNP200 MKKS SMC1A PRMT7 CNGB1 MEGF8 CLRN1 TTC8 MAPK8IP3 TRAF7 AKT2 SETD2 IQSEC2 PCNT PPARG P2RY11 HESX1 BBS10 NDN POMC RAB23 MECP2 SOX10 PRPH2 PTCHD1 KCNJ18 BBS2 INS ACADVL LIPE KMT2D DHDDS WNT4 HLA-DQB1 MKRN3-AS1 KLF11 IDH3B TUB BBIP1 CCDC141 FRMPD4 CNGA1 ARL13B ADCY3 ACSL4 SNRPN PHF21A GNAS GNAS TBX3 STX16 ARL3 SH2B1 TUB SMO HUWE1 SHOX CYP7A1 NEK2 PRPF3 PAK3 RDH12 TCF20 USP8 IFT172 BBIP1 FGF8 ADNP IFT27 CYP19A1 ARHGEF18 RREB1 ABCA4 SLC10A7 PDGFB LRAT ARVCF PKDCC IQSEC2 MTFMT CLIP2 C8ORF37 SIM1 TBX1 BEST1 PIGT SETD5 PDSS1 EHMT1 SPG11 SCAPER ZNF408 RPS6KA3 SIM1 SH2B1 BAZ1B BRAF SLC25A4 P4HTM CEP290 C8ORF37 APPL1 UPF3B ENPP1 TRIM32 AFF4 SMARCE1 RFC2 AIP RNPC3 PRCD DHX38 UCP3 IFT172 BBS5 SLC7A14 PDE4D ATRX WT1 FAM161A ANOS1 SHANK3 IFT172 FGFR1 ZNF711 MC4R LEP DLG3 NSMF PNKP GNAS MAGEL2 RPS6KA3 KIZ SLC7A7 ADRB2 RAI1 MEGF8 AFF4 HDAC8 FXR1 GNAS CLCN4 PSMD12 PHF6 OFD1 PAX4 TRIP12 MAGEL2 GABRD EP300 TRAPPC9 SOX3 PHIP PTEN KCNAB2 WAC NDNF FGF17 ARMC5 HDAC4 SH3KBP1 IMPG2 LARS2 HACE1 ADNP AGRP LEPR PROK2 IL17RD AGBL5 USP8 TERT BPTF THOC2 PIK3CA SKI AHR TRAPPC9 CRX CRB1 PRMT7 KISS1R NF2 COMT TBX1 IMPDH1 SMAD4 BBS1 GTF2IRD1 EIF2S3 BBS1 PRPF31 PCSK1 KLHL7 DEAF1 COL10A1 AKT2 SMC3 CCDC28B CUL4B ABCC8 FLII DPYD PDE4D NRL PDE6G RBP3 MRAP2 AGTR2 VPS13B KDM6A IPW IGFALS PROKR2 MECP2 XRCC4 TRIM32 FGFR1 SPRY4 MKS1 ALG13 HGSNAT CERKL AKT1 RHO IDH3A RP1L1 EHMT1 EP300 PWRN1 IGF1 TACR3 SIN3A EYS EIF2S3 BBS4 IL1RAPL1 LAS1L IFT88 ARL6 CREBBP AHI1 CHD7 ELN CEP19 ARL6 PRPF8 SLC9A7 PCSK1 MAK SRY DNMT3A HACE1 HLA-DRB1 TTC8 TNFSF4 DYRK1B FOXP1 KIDINS220 OFD1 TBL2 BDNF RGR FSCN2 HIRA GHR NTRK2 IQSEC2 IFT74 ZNF81 XYLT1 ALB PRDM16 IFT140 IFT27 MAN1B1 ARX PDE4D SIM1 GCK IGF1R CANT1 SH2B1
    Protein Mutations 3
    G20210A P12A W64R

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0001513: Obesity
    Genes 490
    NR2E3 WT1 LMNA TBX3 POGZ PROK2 DCC MID2 SDCCAG8 ZNF41 RAB39B LIMK1 CNKSR2 PRPF4 PDE11A RP2 USP27X BBS10 CTNNB1 KIDINS220 FGFR3 XYLT1 PDE6B TOPORS GP1BB BBS7 GATA4 ARL2BP KCNJ11 MLXIPL HS6ST1 CEP290 GHRL EGF TAF1 PRKAR1A SEC24C PROM1 BBS12 POMC NPHP1 CARTPT C8ORF37 APOE DMD ZBTB20 BBS2 SYNE2 BLK UBE3A CCDC141 TMEM43 FTSJ1 HCFC1 FEZF1 SOX2 CACNA1S CDH23 BBS7 EMD ELN IFT172 CEL MAGEL2 TMEM67 JMJD1C UFD1 NIN ARMC5 CREBBP MKKS PDE6A BAP1 FHL1 GTF2I NEUROD1 USH2A SIN3A KIF7 RBMX PCARE CXORF56 EXOC6B MCM3AP LEP TBX1 HERC2 MED12 PDX1 OTX2 USP9X ARL6 LZTFL1 PWAR1 ADRB3 BBS9 RPE65 REEP6 RLBP1 HNF1A ERMARD TTC8 POMGNT1 INPP5E WDPCP CUL4B SAG SDCCAG8 SDC3 HESX1 KMT2A BLK RAD21 SEMA4A MOG ATP6AP2 CEP164 ARL6 BBS12 POMC MAN1B1 CTSH ALMS1 HSD11B1 NPAP1 CDHR1 RERE BLM HCRT ARNT2 FLRT3 BBS4 ROM1 SNORD116-1 ARHGEF6 ZNF711 ZNF513 GDI1 GNAS VPS13B RP1 FTO DDX6 PCNT POU3F4 TULP1 DUSP6 MC4R PNPLA6 SYP CREBBP SPATA7 LMNA GABRA3 H6PD CA4 NIPBL GNAS MKRN3 FMR1 SNORD115-1 RP9 MC3R MKS1 BBS2 PHF6 SUFU GNAS-AS1 WDR11 TSPAN7 MERTK GNAS MTTP PRPF6 NR0B2 GNAS BAP1 PRKAR1A MYT1L HNF4A RAI1 DYNC2I2 RPGR BBS9 SMARCB1 NKAP RAB23 GUCA1B LAS1L ZNF365 ALMS1 PAX6 HDAC8 ATRX TRAF3IP1 HDAC8 KIAA1549 CNNM2 PROKR2 MOG SEMA3A BBS5 PAX6 LEPR LZTFL1 SYNE1 SNRNP200 MKKS SMC1A PRMT7 CNGB1 MEGF8 CLRN1 TTC8 MAPK8IP3 TRAF7 AKT2 SETD2 IQSEC2 PCNT PPARG P2RY11 HESX1 BBS10 NDN POMC RAB23 MECP2 SOX10 PRPH2 PTCHD1 KCNJ18 BBS2 INS ACADVL LIPE KMT2D DHDDS WNT4 HLA-DQB1 MKRN3-AS1 KLF11 IDH3B TUB BBIP1 CCDC141 FRMPD4 CNGA1 ARL13B ADCY3 ACSL4 SNRPN PHF21A GNAS GNAS TBX3 STX16 ARL3 SH2B1 TUB SMO HUWE1 SHOX CYP7A1 NEK2 PRPF3 PAK3 RDH12 TCF20 USP8 IFT172 BBIP1 FGF8 ADNP IFT27 CYP19A1 ARHGEF18 RREB1 ABCA4 SLC10A7 PDGFB LRAT ARVCF PKDCC IQSEC2 MTFMT CLIP2 C8ORF37 SIM1 TBX1 BEST1 PIGT SETD5 PDSS1 EHMT1 SPG11 SCAPER ZNF408 RPS6KA3 SIM1 SH2B1 BAZ1B BRAF SLC25A4 P4HTM CEP290 C8ORF37 APPL1 UPF3B ENPP1 TRIM32 AFF4 SMARCE1 RFC2 AIP RNPC3 PRCD DHX38 UCP3 IFT172 BBS5 SLC7A14 PDE4D ATRX WT1 FAM161A ANOS1 SHANK3 IFT172 FGFR1 ZNF711 MC4R LEP DLG3 NSMF PNKP GNAS MAGEL2 RPS6KA3 KIZ SLC7A7 ADRB2 RAI1 MEGF8 AFF4 HDAC8 FXR1 GNAS CLCN4 PSMD12 PHF6 OFD1 PAX4 TRIP12 MAGEL2 GABRD EP300 TRAPPC9 SOX3 PHIP PTEN KCNAB2 WAC NDNF FGF17 ARMC5 HDAC4 SH3KBP1 IMPG2 LARS2 HACE1 ADNP AGRP LEPR PROK2 IL17RD AGBL5 USP8 TERT BPTF THOC2 PIK3CA SKI AHR TRAPPC9 CRX CRB1 PRMT7 KISS1R NF2 COMT TBX1 IMPDH1 SMAD4 BBS1 GTF2IRD1 EIF2S3 BBS1 PRPF31 PCSK1 KLHL7 DEAF1 COL10A1 AKT2 SMC3 CCDC28B CUL4B ABCC8 FLII DPYD PDE4D NRL PDE6G RBP3 MRAP2 AGTR2 VPS13B KDM6A IPW IGFALS PROKR2 MECP2 XRCC4 TRIM32 FGFR1 SPRY4 MKS1 ALG13 HGSNAT CERKL AKT1 RHO IDH3A RP1L1 EHMT1 EP300 PWRN1 IGF1 TACR3 SIN3A EYS EIF2S3 BBS4 IL1RAPL1 LAS1L IFT88 ARL6 CREBBP AHI1 CHD7 ELN CEP19 ARL6 PRPF8 SLC9A7 PCSK1 MAK SRY DNMT3A HACE1 HLA-DRB1 TTC8 TNFSF4 DYRK1B FOXP1 KIDINS220 OFD1 TBL2 BDNF RGR FSCN2 HIRA GHR NTRK2 IQSEC2 IFT74 ZNF81 XYLT1 ALB PRDM16 IFT140 IFT27 MAN1B1 ARX PDE4D SIM1 GCK IGF1R CANT1 SH2B1
    Protein Mutations 3
    G20210A P12A W64R

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook